Global Nasal Drug Delivery Systems Market - 2024-2031

Global Nasal Drug Delivery Systems Market - 2024-2031

Global Nasal Drug Delivery Systems Market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031

Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration. This is due to the large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism, and ready accessibility.

Market Dynamics: Drivers & Restraints

Increasing product approvals by regulatory authorities

The global nasal drug delivery systems market is anticipated to increase as a result of rising product approvals by regulatory bodies and new products launched by major players.

For instance, in March 2023, Pfizer stated that the Food and Drug Administration approved a nasal spray for the treatment of migraines that employs a different therapy from other nasal solutions available for the relief of severe headache pain.

According to clinical trial findings that were published in the journal Lancet Neurology, the fast-acting medication, zavegepant, which will be marketed as Zavzpret, outperformed a placebo in terms of reducing pain and patients' most irritating symptoms. 30 minutes to two hours after taking the medicine, trial participants who took it were more likely to report resuming normal function.

Furthermore, global nasal drug delivery systems are also driven by various other factors like a rise in the advancements in the devices, novel product launches by key players and others helping the market to grow during the forecast period.

Patients' inexperience with the method of dosage administration

Although DPIs and MDIs have demonstrated their effectiveness in providing precise dose formulations, patient population ignorance of such nasal medication delivery strategies is leading to failures. The misuse of the drug delivery system is the most frequent problem. Unawareness is a result of a lack of knowledge and older persons' comprehension issues.

The patient's health will unavoidably be impacted by this improper use and subsequent underdosing, which will result in little use of the drug delivery device. The entire market revenue throughout the predicted period might suffer as a result.

Segment Analysisn

The global nasal drug delivery systems market is segmented based on dosage form, type, application, formulation type, distribution channel and region.

The nasal spray from the dosage form segment accounted for approximately 41.7 % of the nasal drug delivery systems market share

The nasal spray from the Dosage Form segment accounted for approximately 41.7 %. The market growth of the nasal spray market is expected to increase due to rising demand for self-administration and increased patient compliance. The long-lasting nasal spray reduces swelling and mucus, but overuse can cause headaches, coughing, nasal passage inflammation, sinus infections, and occasionally nasal membrane tears.

For instance, in August 2023, Emergent BioSolutions Inc. stated that NARCAN Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September. Over-the-counter (OTC) access to NARCAN Nasal Spray offers more people the ability to respond in an opioid emergency, helping to save lives and keep loved ones and communities safe.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like asthma and chronic obstructive pulmonary diseases becoming more prevalent, and early treatment measures are being widely used. Chronic obstructive pulmonary disease is the third leading cause of death in the U.S. Therefore, the rising incidence of COPD may encourage more people to utilize nasal drug delivery devices. Also, product launches by key players, FDA approvals and others help the region to have the highest market share during the forecast period.

For instance, on December 22, 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.), announced the launch of a generic version of Narcan1 (naloxone hydrochloride nasal spray). Moreover, naloxone hydrochloride nasal spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose with signs of breathing problems or inability to respond.

Covid 19 Impact Analysis

The COVID-19 pandemic had a positive effect on the nasal drug delivery systems market since many patients desired to complete their chronic respiratory illness drug therapy at home. As a result, more people used inhalers at home than in hospitals or outpatient clinics. Nasal inhalers are now more frequently used to treat conditions such as asthma, migraines, and other mental diseases. Additionally, several pharmaceutical companies have been involved in the development of vaccines employing nasal drug delivery technology, and several of them are currently undergoing clinical trials.

Market Segmentation

By Dosage form
• Nasal drops
• Nasal sprays
• Nasal gels
• Nasal suspensions & emulsions
• Nasal powders
• Nasal particles
• Others

By Type
• Multi Dose
• Bi Dose
• Unit Dose

By Application
• Rhinitis
• Nasal Congestion
• Asthma
• Others

By Formulation type
• Drugs
• Viscosifying agents
• Solubilizers
• Surfactants
• Bio-adhesive polymers
• Preservatives
• Antioxidants

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include GlaxoSmithKline(GSK) PLC, AstraZeneca PLC, 3M Pharmaceuticals Inc, Pfizer Inc, Becton, Dickinson and Company, OptiNose Inc, Novartis International AG, B.F. Ascher & Company, Inc., Aptar Inc and among others.

Key Developments

 In January 2023, Aptar Pharma, part of AptarGroup, Inc. a global leader in drug delivery systems, services and active material science solutions, stated the launch of APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations.

Why Purchase the Report?
• To visualize the global nasal drug delivery systems market segmentation based on dosage form, type, application, formulation type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of nasal drug delivery systems market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global nasal drug delivery systems market report would provide approximately 64 tables, 61 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies